Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 6/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | TGFBR1 | P36897 | 11/20 | 0.43 |
| ▸ | TGFBR2 | P37173 | 8/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.43 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25228370 | 0.88 | MAPK14 (0.53) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL25207936 | 0.86 | TGFBR1 (0.48) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL17863745 | 0.82 | TGFBR1 (0.53) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL25211887 | 0.80 | TGFBR1 (0.51) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL17840720 | 0.79 | TGFBR1 (0.68) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL17840850 | 0.75 | TGFBR1 (0.74) | MAPK14TGFBR1TGFBR2PRKD1MAPK13 | |
| SCHEMBL25217309 | 0.74 | MET (0.49) | METTGFBR1TGFBR2TLR9TLR8 | |
| SCHEMBL30365622 | 0.74 | MET (0.49) | MAPK14METTGFBR1TGFBR2PRKD1 | |
| SCHEMBL25249802 | 0.74 | RAF1 (0.51) | METTGFBR1TGFBR2TLR9TLR8 | |
| SCHEMBL25201249 | 0.74 | MET (0.49) | MAPK14METTGFBR1TGFBR2PRKD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2026-03-03 | — | — | US | disclosed |
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| EP-4188928-B1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | BAYER AG (DE) | 2024-07-24 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-26 | — | — | US | disclosed |
| EP-4188928-A1 | SUBSTITUTED 1 H-PYRROLO[3,2-B]PYRIDIN COMPOUNDS AND METHODS OF USE THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | MAPK14 3249/4885MET 1000/4885TGFBR1 4404/4885 |
| US-12565496-B2 | Substituted 1H-pyrrolo[3,2-b]pyridine compounds and methods of use thereof | CYP1B1, CBR1, CYP4B1 | MAPK14 3698/4885MET 61/4885TGFBR1 3324/4885 |
| US-20230339939-A1 | SUBSTITUTED 1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | CYP1B1, CYP4B1, CYP2C19 | MAPK14 2540/4885MET 4116/4885TGFBR1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.